アジア太平洋地域のバイオ医薬品賦形剤の市場規模は2023年に7億6,120万ドルと評価され、2024年から2030年にかけて5.8%のCAGRで成長すると予測されます。この成長要因としては、この地域の製薬業界の拡大、機能性賦形剤の進歩、および希少疾病用医薬品の使用の増加が堅調な成長見通しを後押ししていることなどがあります。さらに、多機能賦形剤の出現と、医薬品製造の中国やインドなどの新興市場へのシフトが、これらの見通しをさらに高めています。さらに、APACで急成長しているバイオシミラー業界は、バイオ医薬品製剤に使用される賦形剤に新たな機会を提供しています。
目次
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Asia Pacific Biopharma Excipient Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Asia Pacific Biopharma Excipient Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. Asia Pacific Biopharma Excipient Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Asia Pacific Biopharma Excipient Market: Product Movement Analysis, USD Million, 2023 & 2030
4.3. Solubilizers & Surfactants/Emulsifiers
4.3.1. Solubilizers & Surfactants/Emulsifiers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Polyols
4.4.1. Polyols Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Carbohydrates
4.5.1. Carbohydrates Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Specialty Biopharma Excipients/Others
4.6.1. Specialty Biopharma Excipients/Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Asia Pacific Biopharma Excipient Market: Regional Estimates & Trend Analysis
5.1. Asia Pacific Biopharma Excipient Market Share, By Region, 2023 & 2030, USD Million
5.2. Asia Pacific
5.2.1. Asia Pacific Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.2. Japan
5.2.2.1. Japan Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.3. China
5.2.3.1. China Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.4. India
5.2.4.1. India Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.5. Malaysia
5.2.5.1. Malaysia Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.6. South Korea
5.2.6.1. South Korea Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.7. Philippines
5.2.7.1. Philippines Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.8. New Zealand
5.2.8.1. New Zealand Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.9. Australia
5.2.9.1. Australia Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.10. Singapore
5.2.10.1. Singapore Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.11. Indonesia
5.2.11.1. Indonesia Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis by Key Market Participants
6.2. Company Categorization
6.3. Company Heat Map Analysis
6.4. Company Profiles
6.4.1. Signet Excipients Pvt. Ltd.
6.4.1.1. Participant’s Overview
6.4.1.2. Financial Performance
6.4.1.3. Product Benchmarking
6.4.1.4. Recent Developments/ Strategic Initiatives
6.4.2. ABITEC
6.4.2.1. Participant’s Overview
6.4.2.2. Financial Performance
6.4.2.3. Product Benchmarking
6.4.2.4. Recent Developments/ Strategic Initiatives
6.4.3. Sigachi Industries.
6.4.3.1. Participant’s Overview
6.4.3.2. Financial Performance
6.4.3.3. Product Benchmarking
6.4.3.4. Recent Developments/ Strategic Initiatives
6.4.4. Roquette Frères
6.4.4.1. Participant’s Overview
6.4.4.2. Financial Performance
6.4.4.3. Product Benchmarking
6.4.4.4. Recent Developments/ Strategic Initiatives
6.4.5. Colorcon
6.4.5.1. Participant’s Overview
6.4.5.2. Financial Performance
6.4.5.3. Product Benchmarking
6.4.5.4. Recent Developments/ Strategic Initiatives
6.4.6. Meggle GmbH & Co. KG
6.4.6.1. Participant’s Overview
6.4.6.2. Financial Performance
6.4.6.3. Product Benchmarking
6.4.6.4. Recent Developments/ Strategic Initiatives
6.4.7. CLARIANT
6.4.7.1. Participant’s Overview
6.4.7.2. Financial Performance
6.4.7.3. Product Benchmarking
6.4.7.4. Recent Developments/ Strategic Initiatives
6.4.8. DFE Pharma
6.4.8.1. Participant’s Overview
6.4.8.2. Financial Performance
6.4.8.3. Product Benchmarking
6.4.8.4. Recent Developments/ Strategic Initiatives
6.4.9. SPI Pharma
6.4.9.1. Participant’s Overview
6.4.9.2. Financial Performance
6.4.9.3. Product Benchmarking
6.4.9.4. Recent Developments/ Strategic Initiatives
6.4.10. IMCD.
6.4.10.1. Participant’s Overview
6.4.10.2. Financial Performance
6.4.10.3. Product Benchmarking
6.4.10.4. Recent Developments/ Strategic Initiatives
6.4.11. Spectrum Chemical
6.4.11.1. Participant’s Overview
6.4.11.2. Financial Performance
6.4.11.3. Product Benchmarking
6.4.11.4. Recent Developments/ Strategic Initiatives
6.4.12. Pharmonix
6.4.12.1. Participant’s Overview
6.4.12.2. Financial Performance
6.4.12.3. Product Benchmarking
6.4.12.4. Recent Developments/ Strategic Initiatives
6.4.13. BASF SE
6.4.13.1. Participant’s Overview
6.4.13.2. Financial Performance
6.4.13.3. Product Benchmarking
6.4.13.4. Recent Developments/ Strategic Initiatives
